StreetInsider.com News Articles

Form 4 Inhibrx Biosciences, For: Oct 14 Filed by: Lappe Mark

Wed, 14 Oct 2026 18:58:00 -0400

si-local-file:///var/storage/secattach/20261014/27188140.html

Inhibrx Announces Participation in Upcoming Scientific Conferences

Tue, 13 Oct 2026 16:00:00 -0400

SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:

Inhibrx Announces Participation in Upcoming Scientific Conferences

Tue, 13 Oct 2026 16:00:00 -0400

Form 4 Inhibrx Biosciences, For: Sep 25 Filed by: Lappe Mark

Mon, 28 Sep 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260928/27115693.html

Form 8-K Inhibrx Biosciences, For: Sep 28

Mon, 28 Sep 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260928/27115389.html

Form 4 Inhibrx Biosciences, For: Sep 23 Filed by: Kayyem Jon Faiz

Wed, 23 Sep 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260923/27097282.html

Form 4/A Inhibrx Biosciences, For: Jun 03 Filed by: Vuori Kristiina MD

Fri, 18 Sep 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260918/27080814.html

Form 4/A Inhibrx Biosciences, For: Jun 03 Filed by: FORSYTH DOUGLAS

Fri, 18 Sep 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260918/27080822.html

Form 4/A Inhibrx Biosciences, For: Jun 03 Filed by: MANHARD KIMBERLY

Fri, 18 Sep 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260918/27080784.html

Form 4/A Inhibrx Biosciences, For: Jun 03 Filed by: Kayyem Jon Faiz

Fri, 18 Sep 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260918/27080768.html

Inhibrx Biosciences (INBX) Reiterated at Market Perform by Citizens on INBRX-106 Ph2 Results

Fri, 18 Sep 2026 05:09:52 -0400

Citizens analyst Reni Benjamin reiterated a Market Perform rating on Inhibrx Biosciences (NASDAQ: INBX).

The analyst commented. "We maintain our Market Perform rating on Inhibrx Biosciences based on a revenue and earnings multiple analysis, in addition to a cash/share and platform value analysis. Recently, Inhibrx reported updated Phase 2 results evaluating INBRX-106 in combination with pembrolizumab (pembro) in r/m HNSCC. While the combination outperformed the pembro control arm and a subset of HPV+ patients substantially outperformed, we continue to view a changing landscape and the timeline to complete the next clinical trial as potential near-term hurdles. Even though Inhibrx is well

Form 4 Inhibrx Biosciences, For: Sep 16 Filed by: Kayyem Jon Faiz

Thu, 17 Sep 2026 17:47:00 -0400

si-local-file:///var/storage/secattach/20260917/27076957.html

Form 4 Inhibrx Biosciences, For: Sep 11 Filed by: MANHARD KIMBERLY

Tue, 15 Sep 2026 17:53:00 -0400

si-local-file:///var/storage/secattach/20260915/27065973.html

Form 144 Inhibrx Biosciences, Filed by: MANHARD KIMBERLY

Tue, 15 Sep 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260915/27064777.html

Form 144 Inhibrx Biosciences, Filed by: MANHARD KIMBERLY

Mon, 14 Sep 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260914/27059110.html

Form 144 Inhibrx Biosciences, Filed by: MANHARD KIMBERLY

Fri, 11 Sep 2026 13:16:00 -0400

si-local-file:///var/storage/secattach/20260911/27052147.html

Form 4 Inhibrx Biosciences, For: Sep 08 Filed by: MANHARD KIMBERLY

Thu, 10 Sep 2026 19:06:00 -0400

si-local-file:///var/storage/secattach/20260910/27049723.html

H.C. Wainwright Reiterates Buy Rating on Inhibrx Biosciences (INBX)

Wed, 09 Sep 2026 07:30:00 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $245.00 price target on Inhibrx Biosciences (NASDAQ: INBX).

The analyst commented: "Yesterday, Inhibrx announced the primary endpoint results from the Phase 2 portion of the Phase 2/3 HexAgon-HN trial, which is evaluating INBRX-106 plus Keytruda (pembrolizumab) in 1L R/M PD-L1+ (CPS>20) HNSCC. As seen in the presentation, the INBRX-106 combo (n=29) elicited a 48.3% cORR and 9.6-month mPFS (72.4% 6-month PFS rate) vs a 26.5% cORR and 4.9-month mPFS (42.8% 6-month PFS rate) for Keytruda alone (n=34). In the HPV+ subgroup, the INBRX-106 combo (n=10) performed extremely well, with an 80%

Inhibrx drug INBRX-106 shows higher response rate in head and neck cancer

Tue, 08 Sep 2026 07:41:28 -0400

Inhibrx Biosciences, Inc. (Nasdaq: INBX) announced results from the randomized Phase 2 portion of its HexAgon study, showing that INBRX-106 combined with pembrolizumab produced a confirmed objective response rate (cORR) of 48.3% in patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC), compared with 26.5% for pembrolizumab alone.

The data, with a cutoff of August 19, 2026, included 63 evaluable patients across more than 80 study sites in the United States, Europe, and Asia. Median progression-free survival (PFS) was 9.6 months in the combination arm versus 4.9 months for pembrolizumab alone, with six-month PFS rates of 72.4%

Inhibrx drug INBRX-106 shows higher response rate in head and neck cancer

Tue, 08 Sep 2026 07:41:28 -0400

Inhibrx drug INBRX-106 shows higher response rate in head and neck cancer

Tue, 08 Sep 2026 07:41:28 -0400

Inhibrx drug INBRX-106 shows higher response rate in head and neck cancer

Tue, 08 Sep 2026 07:41:28 -0400

Inhibrx Biosciences (INBX) Reiterated at Market Perform by Citizens as Ozekibart Ph1 Started

Thu, 27 Aug 2026 04:32:44 -0400

Citizens analyst Reni Benjamin reiterated a Market Perform rating on Inhibrx Biosciences (NASDAQ: INBX).

The analyst commented, "We maintain our Market Perform rating on Inhibrx Biosciences based on a revenue and earnings multiple analysis, in addition to a cash/share and platform value analysis. Recently, Inhibrx reported 2Q26 financial results and provided corporate updates, including the initiation of two Phase 1 cohorts evaluating ozekibart in CRC. With $219.5MM (pro-forma) in cash, Inhibrx is well-capitalized to continue developing ozekibart and INBRX-106 to key milestones expected in 2026 and 2027. That said, with increasing competition in both the HNSCC and CRC landscape, and the

H.C. Wainwright Starts Inhibrx Biosciences (INBX) at Buy

Mon, 24 Aug 2026 06:07:39 -0400

H.C. Wainwright analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ: INBX) with a Buy rating and a price target of $245.00.

For an analyst ratings summary and ratings history on Inhibrx Biosciences click here. For more ratings news on Inhibrx Biosciences click here.

Shares of Inhibrx Biosciences closed at $103.63 yesterday.

H.C. Wainwright Starts Inhibrx Biosciences (INBX) at Buy

Mon, 24 Aug 2026 06:07:39 -0400

H.C. Wainwright analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ: INBX) with a Buy rating and a price target of $245.00.

For an analyst ratings summary and ratings history on Inhibrx Biosciences click here. For more ratings news on Inhibrx Biosciences click here.

Shares of Inhibrx Biosciences closed at $103.63 yesterday.